9,004
Views
33
CrossRef citations to date
0
Altmetric
Psychiatry

The burden of disease in early schizophrenia – a systematic literature review

ORCID Icon, , , , ORCID Icon, , , , ORCID Icon & show all
Pages 109-121 | Received 24 Mar 2020, Accepted 21 Oct 2020, Published online: 13 Nov 2020

References

  • Ayesa-Arriola R, de la Foz VO-G, Martínez-García O, et al. Dissecting the functional outcomes of first episode schizophrenia spectrum disorders: a 10-year follow-up study in the PAFIP cohort. Psychol Med. 2019;18:1–14.
  • James SL, Abate D, Abate KH, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789–1858.
  • World Health Organization (WHO). Schizophrenia; [cited 2020 Jun 15]. Available from: https://www.who.int/en/news-room/fact-sheets/detail/schizophrenia.
  • Millier A, Schmidt U, Angermeyer MC, et al. Humanistic burden in schizophrenia: a literature review. J Psychiatr Res. 2014;54:85–93.
  • Mayoral‐van Son J, Juncal‐Ruiz M, Ortiz‐García de la Foz V, et al. Understanding the direct and indirect costs of a first episode of psychosis program: insights from PAFIP of Cantabria, Spain, during the first year of intervention. Early Intervent Psychiatry. 2019;13(5):1182–1190.
  • Jääskeläinen E, Juola P, Hirvonen N, et al. A systematic review and meta-analysis of recovery in schizophrenia. Schizophr Bull. 2013;39(6):1296–1306.
  • Karson C, Duffy RA, Eramo A, et al. Long-term outcomes of antipsychotic treatment in patients with first-episode schizophrenia: a systematic review. Neuropsychiatr Dis Treat. 2016;12:57–67.
  • Murru A, Carpiniello B. Duration of untreated illness as a key to early intervention in schizophrenia: a review. Neurosci Lett. 2018;669:59–67.
  • Penttilä M, Jääskeläinen E, Hirvonen N, et al. Duration of untreated psychosis as predictor of long-term outcome in schizophrenia: systematic review and meta-analysis. Br J Psychiatry. 2014;205(2):88–94.
  • Penttilä M, Miettunen J, Koponen H, et al. Association between the duration of untreated psychosis and short-and long-term outcome in schizophrenia within the Northern Finland 1966 Birth Cohort. Schizophr Res. 2013;143(1):3–10.
  • Correll CU, Galling B, Pawar A, et al. Comparison of early intervention services vs treatment as usual for early-phase psychosis: a systematic review, meta-analysis, and meta-regression. JAMA Psychiatry. 2018;75(6):555–565.
  • Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264–269.
  • Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health. 1998;52(6):377–384.
  • Crebbin K, Mitford E, Paxton R, et al. First-episode drug-induced psychosis: a medium term follow up study reveals a high-risk group. Soc Psychiatry Psychiatr Epidemiol. 2009;44(9):710–715.
  • Crebbin K, Mitford E, Paxton R, et al. First-episode psychosis: An epidemiological survey comparing psychotic depression with schizophrenia. J Affect Disorders. 2008;105(1–3):117–124.
  • Kirkbride JB, Croudace T, Brewin J, et al. Is the incidence of psychotic disorder in decline? Epidemiological evidence from two decades of research. Int J Epidemiol. 2009;38(5):1255–1264.
  • Louhija U-M, Saarela T, Juva K, et al. Brain atrophy is a frequent finding in elderly patients with first episode psychosis. Int Psychogeriatr. 2017;29(11):1925–1929.
  • Mule A, Sideli L, Capuccio V, et al. Low incidence of psychosis in Italy: confirmation from the first epidemiological study in Sicily. Soc Psychiatry Psychiatr Epidemiol. 2017;52(2):155–162.
  • Owoeye O, Kingston T, Scully PJ, et al. Epidemiological and clinical characterization following a first psychotic episode in major depressive disorder: comparisons with schizophrenia and bipolar I disorder in the Cavan-Monaghan First Episode Psychosis Study (CAMFEPS). Schizophr Bull. 2013;39(4):756–765.
  • Reay R, Mitford E, McCabe K, et al. Incidence and diagnostic diversity in first-episode psychosis. Acta Psychiatr Scand. 2010;121(4):315–319.
  • Stralin P, Hetta J. Medication, hospitalizations and mortality in 5 years after first-episode psychosis in a Swedish nation-wide cohort. Early Interv Psychiatry. 2019;13(4):902–907.
  • Torniainen M, Mittendorfer-Rutz E, Tanskanen A, et al. Antipsychotic treatment and mortality in schizophrenia. Schizophr Bull. 2015;41(3):656–663.
  • Jhung K, Park JY, Song YY, et al. Experiential pleasure deficits in the prodrome: a study of emotional experiences in individuals at ultra-high risk for psychosis and recent-onset schizophrenia. Compr Psychiatry. 2016;68:209–216.
  • Leung JS, Lee TM, Lee CC. Facial emotion recognition in Chinese with schizophrenia at early and chronic stages of illness. Psychiatry Res. 2011;190(2–3):172–176.
  • Shrivastava A, Shah N, Johnston M, et al. Predictors of long-term outcome of first-episode schizophrenia: a ten-year follow-up study. Indian J Psychiatry. 2010;52(4):320–326.
  • Cotton SM, Lambert M, Schimmelmann BG, et al. Differences between first episode schizophrenia and schizoaffective disorder. Schizophr Res. 2013;147(1):169–174.
  • Rowland T, Birchwood M, Singh S, et al. Short-term outcome of first episode delusional disorder in an early intervention population. Schizophr Res. 2019;204:272–303.
  • Hui CL, Lee EH, Chang WC, et al. Delusional disorder and schizophrenia: a comparison of the neurocognitive and clinical characteristics in first-episode patients. Psychol Med. 2015;45(14):3085–3095.
  • Chen DC, Du XD, Yin GZ, et al. Impaired glucose tolerance in first-episode drug-naive patients with schizophrenia: relationships with clinical phenotypes and cognitive deficits. Psychol Med. 2016;46(15):3219–3230.
  • Nyboe L, Vestergaard CH, Moeller MK, et al. Metabolic syndrome and aerobic fitness in patients with first-episode schizophrenia, including a 1-year follow-up. Schizophr Res. 2015;168(1–2):381–387.
  • Sutterland A, Blom M, De Haan L, et al. Studying heart arrhythmias in relation to psychosis (SHARP). Increased prevalence of suspect Brugada ECG in recent onset schizophrenia. Early Intervent Psychiatry. 2014;8(Suppl 1):59.
  • Uz Y, Gulec H. Cardiometabolic risk in Turkish patients with first episode schizophrenia. Klinik Psikofarmakoloji Bulteni. 2014;24(suppl 1):S316.
  • Srivastava S, Bhatia MS, Sharma A. Comparative study of quality of life and metabolic syndrome in schizophrenia patients who are receiving treatment versus antipsychotic naive, first episode patients from a tertiary care hospital. Asian J Psychiatr. 2018;31:121–123.
  • Chang WC, Lau ESK, Chiu SS, et al. Three-year clinical and functional outcome comparison between first-episode mania with psychotic features and first-episode schizophrenia. J Affect Disord. 2016;200:1–5
  • García-Álvarez L, Garcia-Portilla MP, Caso JR, et al. Early versus late stage schizophrenia. What markers make the difference? World J Biol Psychiatry. 2019;20(2):159–165.
  • Zhang XY, Du X, Yin G, et al. Prevalence and clinical correlates of and cognitive function at the time of suicide attempts in first-episode and drug-naive patients with schizophrenia. Austral NZ J Psychiatry. 2018;52(9):864–875.
  • Randall JR, Walld R, Finlayson G, et al. Acute risk of suicide and suicide attempts associated with recent diagnosis of mental disorders: a population-based, propensity score-matched analysis. Can J Psychiatry. 2014;59(10):531–538.
  • Pawelczyk T, Szymanska B, Grancow-Grabka M, et al. Telomere length in blood cells is related to the chronicity, severity, and recurrence rate of schizophrenia. Neuropsychiatr Dis Treat. 2015;11:1493–1503.
  • Kim SJ, Shim JC, Kong BG, et al. Differences in cognitive function and daily living skills between early- and late-stage schizophrenia. Int J Psychiatry Clin Pract. 2015;19(4):245–251.
  • Dubois V, Peuskens J, Geerts P, et al. Clinical outcomes of long-acting risperidone in recent versus long-term diagnosed Belgian schizophrenic patients: results from electronic Schizophrenia Treatment Adherence Registry (e-STAR) and Trial for the Initiation and Maintenance Of REmission in Schizophrenia with risperidone (TIMORES). Early Intervent Psychiatry. 2014;8(1):39–49.
  • Matsuda Y, Sato S, Hatsuse N, et al. Neurocognitive functioning in patients with first-episode schizophrenia 1 year from onset in comparison with patients 5 years from onset. Int J Psychiatry Clin Pract. 2014;18(1):63–69.
  • Mwansisya TE, Yi W, Wang Z, et al. Comparison of psychosocial determinants in inpatients with first-episode and chronic schizophrenia in China. Arch Psychiatr Nurs. 2013;27(1):32–41.
  • Laursen MF, Licht R, Valentin JB, et al. Prognosis of early-onset bipolar disorder compared to early-onset schizophrenia and healthy controls in a nationwide register based study. Early Intervent Psychiatry. 2018;12(Supplement 1):152.
  • Chang CW, Lau ES, Hui LM, et al. Three-year outcome comparison between patients presenting with first-episode psychotic mania and schizophrenia to easy program in Hong Kong. Schizophr Res. 2014;153:S304-S305.
  • Corker EA, Beldie A, Brain C, et al. Experience of stigma and discrimination reported by people experiencing the first episode of schizophrenia and those with a first episode of depression: the FEDORA project. Int J Soc Psychiatry. 2015;61(5):438–445.
  • Softic R, Becirovic E, Mirkovic Hajdukov M. Rehospitalization rate of first episode and chronic schizophrenia patients one year after discharge. Eur Psychiatr. 2016;33(S1):S587–S587.
  • Bliksted V, Fagerlund B, Weed E, et al. Social cognition and neurocognitive deficits in first-episode schizophrenia. JAMA Psychiatry. 2014;71(10):1121–1128.
  • Bliksted V, Frith C, Videbech P, et al. Hyper- and hypomentalizing in patients with first-episode schizophrenia: FMRI and behavioral studies. Psychoneuroendocrinology. 2019;104(2):269–275.
  • Bliksted V, Videbech P, Fagerlund B, et al. The effect of positive symptoms on social cognition in first-episode schizophrenia is modified by the presence of negative symptoms. Neuropsychology. 2017;31(2):209–219.
  • Fervaha G, Agid O, McDonald K, et al. Daily activity patterns in remitted first-episode schizophrenia. Compr Psychiatry. 2014;55(5):1182–1187.
  • Huang ZH, Hou CL, Huang YH, et al. Individuals at high risk for psychosis experience more childhood trauma, life events and social support deficit in comparison to healthy controls. Psychiatry Res. 2019;273:296–302.
  • Bamiso Makanjuola A, Ademola Adeponle B, Ayodele Obembe O. A comparison of quality-of-life in schizophrenia and affective disorder patients in a Nigerian tertiary hospital. Transcult Psychiatry. 2007;44(1):65–78.
  • Sim K, Chan YH, Chong SA, et al. A 24-month prospective outcome study of first-episode schizophrenia and schizoaffective disorder within an early psychosis intervention program. J Clin Psychiatry. 2007;68(9):1368–1376.
  • Agid O, McDonald K, Siu C, et al. Happiness in first-episode schizophrenia. Schizophr Res. 2012;141(1):98–103.
  • Agid O, Siu C, Harvey PD, et al. Treatment outcomes, insight and recovery in first-episode schizophrenia. Schizophr Res. 2014;153:S165–S166.
  • Ballon JS, Kaur T, Marks II, et al. Social functioning in young people at risk for schizophrenia. Psychiatry Res. 2007;151(1–2):29–35.
  • Bougie JK, Malla A, Miguelez M, et al. Real life assessment of abilify maintena (reliam): interim analysis from a Canadian naturalistic study of aripiprazole long-acting injectable in patients with schizophrenia. Value Health. 2017;20(5):A293.
  • Higuchi Y, Sumiyoshi T, Seo T, et al. Associations between daily living skills, cognition, and real-world functioning across stages of schizophrenia; a study with the Schizophrenia Cognition Rating Scale Japanese version. Schizophr Res Cogn. 2017;7:13–18.
  • Jaracz K, Górna K, Rybakowski F. Social functioning in first-episode schizophrenia. A prospective follow-up study. Arch Psychiatry Psychotherapy. 2007;4:19–27.
  • Lee EH, Hui CL, Chang WC, et al. Letter to the editor: comparison of cognitive functions, pre-morbid conditions and clinical characteristics between brief psychotic disorder and schizophrenia. Psychol Med. 2016;46(9):2011–2013.
  • Reavley NJ, Jorm AF. Stigmatizing attitudes towards people with mental disorders: findings from an Australian National Survey of Mental Health Literacy and Stigma. Aust NZ J Psychiatry. 2011;45(12):1086–1093.
  • Reavley NJ, Jorm AF. Stigmatising attitudes towards people with mental disorders: changes in Australia over 8 years. Psychiatry Res. 2012;197(3):302–306.
  • Agid O, McDonald K, Fervaha G, et al. Values in first-episode schizophrenia. Can J Psychiatry. 2015;60(11):507–514.
  • Al-Bataineh R, Crasan A, Purnichi T, et al. Is diagnosis indeed prognosis? 12 months outcome for schizophrenia, schizophreniform and schizoaffective disorder. Eur Neuropsychopharmacol. 2016;26(Suppl. 1):S49–S50.
  • Law CW, Chen EY, Cheung EF, et al. Impact of untreated psychosis on quality of life in patients with first-episode schizophrenia. Qual Life Res. 2005;14(8):1803–1811.
  • Fleischhacker WW, Kane JM, Geier J, et al. Completed and attempted suicides among 18,154 subjects with schizophrenia included in a large simple trial. J Clin Psychiatry. 2014;75(3):e184.
  • Ventriglio A, Gentile A, Bonfitto I, et al. Suicide in the early stage of schizophrenia. Front Psychiatry. 2016;7:116.
  • Hoang U, Stewart R, Goldacre MJ. Mortality after hospital discharge for people with schizophrenia or bipolar disorder: retrospective study of linked English hospital episode statistics, 1999–2006. BMJ. 2011;343(1):d5422–d5422.
  • Nordentoft M, Wahlbeck K, Hällgren J, et al. Excess mortality, causes of death and life expectancy in 270,770 patients with recent onset of mental disorders in Denmark, Finland and Sweden. PLOS One. 2013;8(1):e55176.
  • Tsai KY, Lee CC, Chou YM, et al. The incidence and relative risk of stroke in patients with schizophrenia: a five-year follow-up study. Schizophr Res. 2012;138(1):41–47.
  • Nicholl D, Akhras KS, Diels J, et al. Burden of schizophrenia in recently diagnosed patients: healthcare utilisation and cost perspective. Curr Med Res Opin. 2010;26(4):943–955.
  • Hodgins S, Piatosa MJ, Schiffer B. Violence among people with schizophrenia: phenotypes and neurobiology. In: Neuroscience of Aggression. Springer; 2013. p. 329–368.
  • Newton RR, Nylander AG, Loze JY, et al. Diverse definitions of the early course of schizophrenia—a targeted literature review. NPJ Schizophr. 2018;4(1):21.
  • Ivarsson T, Broberg AG, Arvidsson T, et al. Bullying in adolescence: psychiatric problems in victims and bullies as measured by the Youth Self Report (YSR) and the Depression Self-Rating Scale (DSRS). Nord J Psychiatry. 2005;59(5):365–373.
  • Birchwood M, Smith J, Cochrane R, et al. The social functioning scale the development and validation of a new scale of social adjustment for use in family intervention programmes with schizophrenic patients. Br J Psychiatry. 1990;157(6):853–859.
  • Diener E, Emmons RA, Larsen RJ, et al. The satisfaction with life scale. J Pers Assess. 1985;49(1):71–75.
  • Lyubomirsky S, Lepper HS. A measure of subjective happiness: preliminary reliability and construct validation. Social Indicators Res. 1999;46(2):137–155.
  • Burckhardt CS, Anderson KL. The Quality of Life Scale (QOLS): reliability, validity, and utilization. Health Qual Life Outcomes. 2003;1(1):60.